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ABSTRACT
Introduction: Isoniazid in the regiment treatment of pulmonary tuberculosis patients causes side effects.
Hepatotoxicity is one of the isoniazid’s side effects that need medical attention. Isoniazid-induced
hepatotoxicity has no correlation with high level of isoniazid in plasma. However, several animal studies
show it has an association with hydrazine, a metabolite of isoniazid. The role of hydrazine in isoniazid-
induced hepatotoxicity among tuberculosis patients is unclear.
Objective: The aim of this study was to analyze the correlation of hydrazine and serum glutamic-pyruvic
transaminase (SGPT) levels at two hours after drug administration in the end of intensive phase treatment of
pulmonary tuberculosis patients.
Methods: This was an observational study with cross-sectional design. Fifty eight newly diagnosed pulmonary
tuberculosis patients were enrolled in this study. Venous blood sampling was collected at two hours after
drug administration in the end of intensive phase treatment. SGPT level was measured by an automatic
chemical analyzer. Hydrazine level was measured by using high-performance liquid chromatography (HPLC).
Statistical significance was analyzed using correlation test.
Results and Discussion: The incidence of hepatotoxicity was 3.4% and about 8.6% patients had elevated
SGPT at two hours after drug administration in the end of intensive phase treatment. There was no correlation
between hydrazine level and SGPT levels in this study. These results indicated that hepatotoxicity or minimal
liver damage in some patients might occur in the administration of standard dose isoniazid. It might be
caused by isoniazid’s metabolites itself, or various other factors.
Conclusions: There was no correlation between hydrazine level and SGPT levels at 2 hours after drug
administration in the end of intensive phase treatment in this study.
Keywords: hepatotoxicity, isoniazid, hydrazine, pulmonary tuberculosis
INTISARI
Pendahuluan: Pemberian isonizid dalam regimen pengobatan tuberkulosis paru dapat menyebabkan efek
samping. Hepatotoksisitas merupakan salah satu efek samping yang perlu mendapat perhatian. Hidrazin
merupakan metabolit isoniazid yang diduga merupakan penyebab hepatotoksisitas akibat pemberian isoniazid.
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Studi sebelumnya dengan model hewan coba menunjukkan korelasi kadar hidrazin dan kadar SGPT yang
merupakan parameter penanda hepatotoksisitas. Penelitian-penelitian pada penderita tuberkulosis paru
menunjukkan hasil yang tidak konsisten.
Tujuan: Penelitian ini bertujuan untuk menganalisis korelasi kadar hidrazin dan kadar SGPT dua jam setelah
minum obat pada akhir fase intensif pada pasien tuberkulosis paru.
Metode: Penelitian ini merupakan penelitian observasional dengan rancangan cross-sectional yang diikuti
oleh 58 subyek yang merupakan pasien tuberkulosis paru kasus baru. Pengambilan sampel darah vena
dilakukan pada dua jam setelah minum obat terakhir fase intensif pengobatan tuberkulosis. Kadar SGPT
diukur dengan mesin analisis kimia otomatis, sedangkan kadar isoniazid dan metabolitnya, hidrazin diukur
dengan metode HPLC. Data dianalisis dengan uji korelasi.
Hasil dan Diskusi: Persentase pasien yang mengalami hepatotoksisitas sebesar 3.4% dan sekitar 8,6% pasien
mengalami kenaikan SGPT dua jam setelah minum obat pada akhir fase intensif. Tidak terdapat korelasi
antara kadar hidrazin dan kadar SGPT pada penelitian ini. Hal tersebut menunjukkan bahwa pada pemberian
izoniazid dosis standar masih dapat terjadi hepatotosisitas atau kerusakan hati ringan pada sebagian kecil
pasien, yang disebabkan oleh metabolit isoniazid atau berbagai faktor yang lain.
Simpulan: Tidak ada korelasi kadar hidrazin dan kadar SGPT dua jam setelah minum obat pada terapi akhir
fase intensif pada penelitian ini.
Kata kunci : hepatotoksisitas, isoniazid, hidrazin, tuberkulosis paru
INTRODUCTION
Tuberculosis (TB) is still a major health
problem in the world. Indonesia is a TB endemic
country, with the fifth-highest number of cases
in the world1,2. To treat tuberculosis patients,
combinations of antituberculosis drugs are used
in Indonesia. This treatment gives the good
outcome in general. However, the compliance
of this treatment sometimes is not so good due
to its side effects3.
Isoniazid is one of the effective antituber-
culosis drugs used in the curative and preventive
treatments, as monotherapy or combination
with others. Unfortunately, isoniazid has many
side effects. Hepatotoxicity is one of the
isoniazid’s side effects that need clinical
attention4-6. Hepatotoxicity of isoniazid can be
presented as a mild transient elevation of
aminotransferase in 10-20% patients, to a rare
case of severe hepatotoxicity. Elevated serum
transaminase values are frequent during the first
eight week of therapy7-9.
The exact mechanism of isoniazid-induced
hepatotoxicity is unknown. It has no correlation
with high level of isoniazid in plasma itself and
is considered idiosyncratic. Some studies
proposed that toxic metabolites was responsible
for it10-12. In the body, isoniazid will undergo
acetylation to become acetyl isoniazid.
Subsequently, it will be hydrolyzed into acetyl
hydrazine. A small part of isoniazid is hydrolyzed
directly into hydrazine and then is acetylated
into acetyl hydrazine. Hydrazine is a toxic
metabolites in isoniazid metabolism that could
bind to hepatocytes and cause cell damage12-14.
The studies on the role of toxic metabolite
in isoniazid-induced hepatotoxicity showed
inconsistent results. Previous studies showed
that hydrazine level was correlated with the
markers of hepatotoxicity15-16. Gent et al17 also
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demostrated the increasing of hydrazine level
in isoniazid-induced hepatotoxicity. In the
contrary, Donald et al showed no correlation
between hydrazine level and SGPT level among
32 children with meningitis tuberculosis18.
The aim of this study was to assess the
correlation between hydrazine and SGPT levels
at two hours after drug administration in the




This study was an observational study with
cross-sectional design. A total of 58 newly
diagnosed pulmonary tuberculosis patients,
with age more than 18 years old, were enrolled
in this study. They received standard fixed dose
combination of the tuberculosis treatment
regimen used in Indonesia and comply with
therapy. The baseline serum glutamic-
oxaloacetic transaminase (SGOT), SGPT,
hemoglobin, urea, and creatinine were within
the normal limits. The patients have no hepatitis
B and human immunodeficiency virus infection.
A complete history and physical examination
were performed for all participants. The
demographic characteristics, history of smoking,
concomitant disease and drugs, were also
collected using a standard questionnaire.
Hepatotoxicity was defined as the increasing
levels of SGPT at the end of intensive phase
treatment of tuberculosis three times or more
above the normal value. Delta SGPT was defined
as difference between SGPT level at the baseline
and end of the treatment. Nutritional status was
assessed by measuring body mass index (BMI)
and categorized according to the WHO
classification19.
Normal values of SGOT and SGPT levels were
< 33 U/L and < 50 U/L in male, < 27 U/L and < 34
U/L in female respectively. The hemoglobin level
13.2-17.3 g/dL in male and 11.7-15.5 g/dL in
female were considered normal. Blood urea
nitrogen and creatinine level normally ranged
between 13-43 mg/dL and 0.7-1.2 mg/dL in
male, 17-43 mg/dL and 0.5-0.9 mg/dL in female.
This was reviewed and approved by the
Ethics Committees of Faculty of Medicine,
Universitas Gadjah Mada, Indonesia. This study
was a part of a prospective cohort study of
pharmacovigilance of antituberculosis drugs by
Badan Penelitian dan Pengembangan Kesehatan
(Litbangkes), Kementerian Kesehatan Republik
Indonesia and Indonesia Clinical Epidemiology
and Evidence-Based Medicine (ICE-EBM)
Network. The participants were recruited from
three Balai Pengobatan Paru-paru (BP4) and 13
Puskesmas located in Yogyakarta Province,
during September 2012 to September 2013. All
the participants gave their written inform
consent before enrolled in this study.
Blood sampling
Blood samples were collected two hours
after administration of the fixed dose
combination of the treatment regimen of
tuberculosis at the end of intensive phase.
Plasma was separated and stored at -60p C until
the analysis. The trichloroacetic acid (TCA)
solution (10% w/v) was added into plasma, and
then the admixture was centrifuged. Subs-
equently, ether was added into the
deproteinized sample. An aliquot was added
with cinnamaldehyde 1% (in methanol) with
ratio 4:1 (v/v). After incubation in room
temperature for 26 hours, the sample was
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injected to HPLC. The analytical conditions and
parameters for HPLC used in this study were
same as previously describe by Seifart et al18.
We used Shimadzu HPLC system, LC-20AD
series, with LC-10AT pump model, SPD-20A
detector model, C18 shim-pack VP ODS column
(250 mm x 4.6 mm, i.d. 5µm), and detection
wavelength of 286 nm. The compositions of
mobile phase were methanol and water at ratio
80:20 with flow rate one ml/minutes. Standard
curves were prepared with concentration
variation 0.3; 1.3; 5; 10; 15 ng/mL. Coefficient of
linear correlation was > 0.99. Limit of detection
was 0.40 ng/mL and limit of quantification were
1.35 ng/mL.
Data analysis
Data obtained from this study was
expressed as mean values ± SD, numbers, or
percentages. Categorical variables were
compared using the chi-square test or Fisher’s
exact test. Continuous variables were analyzed
using the independent sample t-test or Mann-
Whitney test. Analysis of correlation between
two values was carried out using Pearson or
Spearman’s test. All statistical tests were based
on a two-tailed probability and p value < 0.05
was considered significant.
The patients’ characteristic is shown in the
Table 1. The age of participants ranged from 19
to 76 years with a mean of 35.9 ± 14.4 years.
The 58.6% of them were males. BMI ranged from
13.78 to 26.95 with a mean of 19.01 ± 3.04. There
were 41.4% subjects classified as underweight.
About 39.7% subjects had history of smoking.
Based on analysis of sputum, about 71.4%
subjects had positive gram stain test. Almost all
the patients (75.9%) received three tablets of
antituberculosis drug. About 5.2% of patients
had a comorbid of diabetes mellitus (DM), and
about 63.8% of them received co-medication.
The type of co-medication is shown in Table 2.
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aFDC, fixed-dose combination
bDM, diabetes mellitus
cSGOT, serum glutamic-oxaloacetic transaminase
dSGPT, serum glutamic-pyruvic transaminase
Table 1. Baseline Characteristics of The Patients
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Table 2. List of co-medications Correlation between hydrazine and SGPT levels
Mean of hydrazine level two hours after
drug administration at the end of intensive
phase was 15.75 ± 2.74 ng/ mL with range 0 –
125.45 ng/ mL. Five patients (8.6%) have elevated
SGPT level at the end of intensive phase. Two of
them were classified as having hepatotoxicity.
Approximately, 51.7% subject had elevated delta
SGPT. Table 3 compares the characteristics
between elevated SGPT group and normal SGPT
group. Among variables analyzed in this study,
only sex variable showed significant difference
between two groups (p = 0.009). All patients with
elevated SGPT level were female. Elevated SGPT
Table 3. Comparison of elevated SGPT group and normal SGPT group.
Data were analyzed by aindependent sample t-test, bMann Whitney test, and Fisher’s exact test. *P value
< 0.05 was considered significant.
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studies showed various results regarding sex as
a risk factor for hepatotoxicity. Some studies
showed female had higher risk to develop
hepatotoxicity 6, 23, while another study showed
female sex is not a risk factor24.
There was no correlation between
hydrazine and SGPT level two hours after drug
administration at the end of intensive phase in
this study. Previous study in rats demonstrated
that hydrazine level correlated with SGPT level
at one hour after administration of isoniazid16.
Another study in rabbits showed that hydrazine
level correlated with arginin succinic acid lipase
(ASAL), a sensitive marker of hepatic necrosis15.
In those study, the dose of isoniazid given to
animals was higher than the dose used in the
treatment of tuberculosis patients, which
ranged from 50 to 100 mg/kg or approximately
10-20 times higher. In the dose of isoniazid 100
mg/kg, hydrazine level in plasma were detected
around 32 ìmol/L or about 1024 µg/mL at 1 hour
after administration of isoniazid. In this study,
hydrazine level two hours after drug
administration was very low, ranged from 0 to
125 ng/mL, possibly due to difference dose of
isoniazid. Hydrazine level of 1 mM
(approximately 32000 ng/mL) cause only
minimal damage to hepatocyte25.
Previous study by Donald et al18. on the
isoniazid-induced hepatotoxicity in 32 children
with meningitis TB, who received isoniazid 20
mg/kg/day, also showed the low levels of
hydrazine and no correlation between hydrazine
levels and liver damage. Preece et al26. showed
that hydrazine accumulation in rat’s hepatocytes
reached toxic level, although hydrazine level in
plasma was undetectable.
group had no higher level of hydrazine or dose
of rifampicin.
Based on Spearman’s test, there was no
correlation between hydrazine level and SGPT
level at two hours after drug administration in
the end of intensive phase (P = 0.311, Figure 1).
Figure 1. Correlation of hydrazine and SGPT level at
the end of intensive phase in all subjects
(n = 58)
The characteristic of the patients in this
study was similar with the pulmonary
tuberculosis patients in Indonesia20-22. The
patients were approximately 40 years old and
were dominated by male. The underweight
patients were relatively common.
The rate of hepatotoxicity in this study was
3.4%, similar with previous study in Yogyakarta20.
There was significant difference in the
proportion of sex between elevated SGPT group
and normal SGPT group. All participants in
elevated SGPT group were female. The previous
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Combination with rifampicin influences the
risk of isoniazid-induced hepatotoxicity.
Rifampicin is known as an inducer of several
cytochromes P450 (CYP) enzymes, including
CYP2E112, 27-28 . Hydrazine levels are higher in
subject with higher rifampicin levels29. In this
study, the mean dose of rifampicin did not differ
between elevated SGPT group and normal SGPT
group. Further investigation is needed to
determine the effect of rifampicin level in plasma
on isoniazid metabolism.
This study had several limitations. Blood
sampling was preformed only one time at two
hours after drug administration in the end of
intensive phase. It might not describe the
fluctuation of drug and metabolite level in blood.
We also could not control the confounding
factors in this study. The data of confounding
factors such as diet and environmental factors
were not analyzed.
CONCLUSIONS
There was no correlation between
hydrazine and SGPT level in two hours after drug
administration at the end of intensive phase
among 58 pulmonary tuberculosis patients.
Further comprehensive investigation with larger
sample size and well controlled confounding
factors, such as poly-morphism in enzyme that
involved in isoniazid metabolism and receptor
in hepatocyte, is needed to determine the role
of toxic metabolite in isoniazid-induce
hepatotoxicity.
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